Amyloidosis Treatment Market

The global amyloidosis treatment market size is anticipated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increased acceptance of new targeted treatments and transplantation, the introduction of biologics, and the growing geriatric population.

Amyloidosis is a disease in which your body accumulates an abnormal protein called amyloid. Amyloid deposits can harm organs and lead them to fail over time. Although this disease is rare, it can be dangerous. Organs that can be affected by Amyloidosis includes heart, kidneys, intestines, joints, liver, nerves, skin, and soft tissues. Amyloid may build up all over your body at times. This is known as systemic amyloidosis, or body-wide amyloidosis. The majority of types of amyloidosis are incurable. Symptoms, on the other hand, can be controlled with therapy. Amyloidosis may not develop symptoms in its early stages. The symptoms that a patient experiences when the condition worsens are determined by the organ or organs that are impacted.

Get Free Sample Report

Accumulation of amyloid in organs causes amyloidosis in general. Which type of condition the patient possesses determines how the amyloid gets there. Amyloidosis are of various types which includes light chain (AL) amyloidosis, autoimmune (AA) amyloidosis, dialysis-related amyloidosis, hereditary (familial) amyloidosis, and senile amyloidosis. For proper diagnosis of amyloidosis doctor might some test which includes blood and urine tests, echocardiogram, biopsy, and bone marrow aspiration & biopsy. Amyloidosis cannot be cured. The goal of treatment is to decrease symptoms by slowing the formation of amyloid proteins. Pain relievers, medications to manage diarrhea, nausea, and vomiting, diuretics to minimize fluid buildup in your body, blood thinners to avoid blood clots, and medicines to control your heart rate are all used to control amyloidosis symptoms. Other therapies are determined by the patient's type of amyloidosis. Amyloidosis is not curable; however, it can be treated, and amyloid levels can be controlled with therapy. Doctors will determine which therapy options are available to the patient and will recommend the most effective treatment. They can make changes as required to help with relieving symptoms and quality of life.

Market Trends, Drivers, Restraints, and Opportunities

• Increased adoption of novel targeted therapies & transplantations and emergence of biologics are projected to boost the market growth during the forecast.
• Growing geriatric population worldwide is anticipated to drive the market growth during the period.
• Technological advancements and improved healthcare facilities in developed countries worldwide, this in turn helps for easy diagnosis of amyloidosis are expected to fuel the market growth.
• Favorable government initiatives and investments are key factors for propelling the market growth.
• High cost of treatment and limited awareness about amyloidosis are anticipated to hamper the market growth during the forecast period.
• Increased R&D investments for novel drugs & treatment development is projected to offer lucrative opportunities for the market players.

Scope of the Report

The report on the global amyloidosis treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Chemotherapy segment is expected to account for a key share
Based on treatment, the amyloidosis treatment market is segmented into chemotherapy, supportive care, surgery, stem cell transplant, and targeted therapy. The chemotherapy segment is expected to account for a key share of the market during the forecast period owing to high rate of hematological remission and long-term disease management.

However, the stem cell transplant, and targeted therapy segment is anticipated to expand at a rapid pace during the forecast period as these treatments are preferred treatments for low-risk patients.

Get Free Sample Report

North America is anticipated to dominate the market
On the basis of regions, the amyloidosis treatment market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to increasing population, rise in patient pool, presence of key manufacturers, and rapid drug development.

On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to increasing demand for supportive care therapeutics, increasing healthcare expenditure, expansion of the pharmaceutical industry, and high rate of acceptance of new products. Furthermore, the large population base with low per capita income has resulted in a strong need for affordable healthcare, which will fuel the growth of chemotherapy generics in this market.

Get Free Sample Report

Segments

• Chemotherapy
• Supportive Care
• Surgery
• Stem Cell Transplant
• Targeted Therapy

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

• Prothena Corporation plc.
• Pfizer Inc.
• Ionis Pharmaceuticals Inc.
• Valeant Pharmaceuticals International Inc.
• Celgene Corporation
• Takeda Pharmaceutical Company Ltd.
• Johnson and Johnson Pvt. Ltd.
• GlaxoSmithKline plc
• Alnylam Pharmaceuticals Inc.
• SOM Innovation Biotech S.L.
• AstraZeneca plc.

Competitive Landscape

Key players competing in the amyloidosis treatment market are Prothena Corporation plc.; Pfizer Inc.; Ionis Pharmaceuticals Inc.; Valeant Pharmaceuticals International Inc.; Celgene Corporation; Takeda Pharmaceutical Company Ltd.; Johnson and Johnson Pvt. Ltd.; GlaxoSmithKline plc; Alnylam Pharmaceuticals Inc.; SOM Innovation Biotech S.L.; and AstraZeneca plc.

Some of the key business strategies includes research & development, mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares.